首页> 外文OA文献 >Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

【2h】

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

机译：复发和难治性结节性淋巴细胞 - 主要霍奇金淋巴瘤：德国霍奇金研究组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Dennis A. Eichenauer; Annette Plütschow; Lena Schröder; Michael Fuchs; Boris Böll; Bastian von Tresckow; Volker Diehl; Peter Borchmann; Andreas Engert;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group [J] . Eichenauer Dennis A., Pluetschow Annette, Schroeder Lena, Blood: The Journal of the American Society of Hematology . 2018,第14期

机译：复发和难治性结节性淋巴细胞 - 主要霍奇金淋巴瘤：德国霍奇金研究组分析
2. Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG) [J] . Eichenauer Dennis A., Pluetschow Annette, Schroeder Lena, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性结节性淋巴细胞为主的霍奇金淋巴瘤：来自德国霍奇金研究组（GHSG）的分析
3. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group [J] . D A Eichenauer, H Goergen, A Plütschow, Leukemia . 2016,第6期

机译：Ofatumumab在复发性结节性淋巴细胞为主的霍奇金淋巴瘤中的治疗：德国霍奇金研究小组的II期研究结果
4. Unusual Presentations of Central Nervous System Non-Hodgkin and Hodgkin Lymphoma: A Clinicopathologic Review of Four Tumours [C] . Lee HY, Chuah KL, Ng SB, International Congress of Neuropathology . 2010

机译：中枢神经系统非霍奇金和霍格金淋巴瘤的不寻常介绍：对四种肿瘤的临床病理综述
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East [O] . Saad Akhtar, M. Shahzad Rauf, Yasser Khafaga, 2021

机译：结节性淋巴细胞 - 主要霍奇金淋巴瘤特征初级和复发/难治性疾病和结果分析的管理：中东的第一个综合报告
7. Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis [O] . Gerber Naamit K., Atoria Coral L., Elkin Elena B., 2015

机译：结节性淋巴细胞为主的霍奇金淋巴瘤患者与典型霍奇金淋巴瘤患者的特征和结果：基于人群的分析

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

著录项

引文网络

相似文献

相关主题

期刊订阅